Skip to main content
. Author manuscript; available in PMC: 2013 Mar 16.
Published in final edited form as: Vaccine. 2012 Feb 1;30(13):2309–2314. doi: 10.1016/j.vaccine.2012.01.058

Table 1.

Factors associated with HPV4 associated seropositivity at baseline among 200 FSWs in Lima, Peru

Variable Baseline
Seronegative
N (%)
Baseline
seropositive
N (%)
P-value
Age* 22.8 (22–23.6) 22.9 (22.6–23.3) 0.73
Education
   Primary 6 (14.3) 11 (7.0) 0.18
   Secondary 24 (57.1) 84 (53.2)
   University/Technical 12 (28.6) 63 (39.9)
BMI* 24.4 (23.5–23.4) 23.4 (23–23.8) 0.03
Ever heard of HPV 23 (54.8) 117 (74.1) 0.02
Marital status single 23 (54.8) 98 (62.0) 0.39
HPV4 DNA positive 3 (7.1) 43 (27.4) <0.01
STD in past year 7 (16.7) 48 (30.4) 0.08
Vaginal discharge 20 (47.6) 61 (38.6) 0.29
Current genital warts 1 (2.4) 12 (7.6) 0.31
Age of first sex under 18 years 36 (85.7) 118 (74.7) 0.15
Years of sex* 7.1 (6.2–7.9) 6.9 (6.5–7.4) 0.79
Clients in past week* 50.7 (16.6–84.9) 40.9 (33.7–48.2) 0.38
Has non-paying partners 28 (66.7) 118 (74.7) 0.30
Number non-paying partners* 0.9 (0.9–1.0) 1.0 (1.0–1.1) 0.15
Any condom use with partners 25 (59.5) 86 (54.4) 0.56
*

mean (95%CI) computed